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http:WHAT THIS PAPER ADDS
This study reports the diagnostic accuracy of ﬂuorescence microlymphography as an adjunct to support the
diagnosis of lymphedema in uncertain cases.Objectives: Fluorescence microlymphography (FML) is a minimally invasive technique for visualization of the
cutaneous lymphatic network. The aim of the study was to assess the accuracy and safety of FML in patients with
unilateral lymphedema.
Methods: This was a cross sectional study. Patients with unilateral leg swelling were assessed and compared with
the unaffected contralateral limb. FML was performed in all index legs and the contralateral leg by injecting
0.1 mL of ﬂuorescein isothiocyanate (FITC)-labeled dextran intradermally in both limbs at the same level. The
most prominent swelling of the affected limb was the anatomical reference. The spread of the dye in the
lymphatic capillaries of the skin was measured in all dimensions by epiluminator intravital microscopy and the
maximum dye spread value 10 min after injection was used for statistical analysis. The contralateral leg served as
control. Test accuracy and receiver operator characteristic (ROC) analysis was performed to assess threshold
values that best predict lymphedema.
Results: Between March 2008 and February 2014 seventy patients with unilateral chronic leg swelling were
clinically diagnosed with lymphedema. The median age was 45 (IQR 27e56) years. Of those, 46 (65.7%) were
female and 71.4% had primary and 28.6% secondary lymphedema. Sensitivity, speciﬁcity, positive and negative
likelihood ratio, and positive and negative predictive value were 94.3%, 78.6%, 4.40, 0.07, 81.5%, and 93.2% for
the 12 mm cut off level and 91.4%, 85.7%, 6.40, 0.10, 86.5%, and 90.9% for the 14 mm cut off level, respectively.
The area under the ROC curve was 0.89 (95% CI: 0.83e0.95). No major adverse events were observed.
Conclusions: FML is an almost atraumatic and safe technique for detecting lymphedema in patients with leg
swelling. In this series the greatest accuracy was observed at a cut off level of 14 mm maximum spread.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Lymphedema is a progressive chronic disease caused by the
anomalous development of the lymphatic system or injury
to the lymphatic system resulting in interstitial accumula-
tion of protein enriched ﬂuid.1 As the disease progresses, it
is characterized by ﬂuid accumulation in the interstitial
space, causing enlargement of the affected area with an
increase in connective and fatty tissue and changes in the
extracellular matrix.2 Millions of people worldwide are
affected by lymphedema, which is a common but oftenresponding author.
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//dx.doi.org/10.1016/j.ejvs.2014.12.033overlooked condition, since there are multiple and often
combined causes for limb swelling.3 Moreover, lymphe-
dema is frequently misdiagnosed, treated too late or not
treated all.4 Thus, early recognition and diagnosis for the
management of lymphedema is important to avoid com-
plications such as functional disability, psychosocial prob-
lems, infection, skin changes, and rarely malignant
transformation.1
Decades ago direct contrast lymphangiography was used
to investigate lymphatic disorders by direct cannulation of
lymph vessels. However, this has been largely abandoned
because of the technical complexity of the procedure, the
challenge to repeat the test, and the unacceptable com-
plications.5,6 Conventional magnetic resonance imaging
(MRI) and computed tomography (CT) scan can be used to
evaluate the presence and severity of edema, but
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other internal medical diseases is not possible. Lympho-
scintigraphy, which has been reported to be 100% speciﬁc
and 92% sensitive for lymphedema remains the standard
diagnostic test for identifying edema of lymphatic origin in
unclear cases.7 However, it involves radiation exposure, is
time consuming, technically challenging, and is not available
at all facilities. This diagnostic test is based on a qualitative
or semi-quantitative evaluation of the lymphatic drainage
and description of the image patterns. Furthermore, the
protocol for lymphoscintigraphy is not standardized and
differs among diagnostic centers.4 Recently, the sensitivity
of lymphoscintigraphy has been reported to be only 62%
and indocyanine green lymphography to be 100% sensitive
and 100% speciﬁc.8 However, these diagnostic techniques
are costly and should only be applied in patients that have a
more complex lymphatic disease. Ideally, an ofﬁce based
test without exposure to ionizing radiation is needed to rule
out or conﬁrm lymphatic disease before sophisticated and
expensive alternative testing.
Fluorescence microlymphography (FML) is a useful ofﬁce
based test in evaluating lymphedema and has been intro-
duced in the early 1980s by Bollinger and collegues.9 This
test has been used in Switzerland over 30 years and is
reimbursed by health insurance.10 The principle is based on
the fact that large molecules in the interstitial space are
primarily drained into and via the lymphatic system. In or-
der to detect the ﬂuid and the lymphatics, a ﬂuorescent
tracer attached to a macromolecule injected into the
interstitial space of the skin was proposed.10 After a pre-
liminary test in the big toe and then in other healthy vol-
unteers, it became evident that intradermal injection of
FITC-labeled (ﬂuorescein isothiocyanate) dextran with a
molecular weight of 150,000 Da was well tolerated and
offered a way to visualize the lymphatic capillary network of
the skin under the epi-illumination microscope.9 Several
studies have shown its value in differentiating between
healthy legs and lymphedema.9,11 The spread of the ﬂuo-
rescent dye has been measured as the maximum distance
of the visualized capillary network from the outer border of
the dye deposit, since this is an easy and readily available
method for quantiﬁcation. Based on its physiologic principle
that macromolecules are drained via the lymphatic capil-
laries into collectors and then deeper lymphatic vessels that
are no longer visible by ﬂuorescent microscopy, a larger
spread of the dye in the cutaneous lymphatic network
suggested a lymphatic disorder. Indeed, a visible capillary
network around the dye deposit with a maximum spread of
12 mm has been has been used as a cut off value be-
tween normal and pathological dye spread due to a
dysfunction of the lymphatic drainage to support the clin-
ical diagnosis of lymphedema.10,12 Despite recognition of
the test at the time, clinical adaptation has been rare so far
and the test is only used in a very few centers. A potential
reason is that not enough clinical data were available. For
example, at that time, no data on sensitivity and speciﬁcity
were presented and potential side effects have not been
systematically reported. The aim of this study was toevaluate the diagnostic accuracy of FML in patients with
unilateral lymphedema and to assess safety.MATERIAL AND METHODS
Patients with unilateral leg swelling and suspicion of lym-
phedema were referred to the vascular unit for further
evaluation. In all patients, history and clinical examination
were assessed by two experienced vascular physicians.
Recognition of cutaneous ﬁndings of lymphedema include
peau d’orange, indicating cutaneous and subcutaneous
ﬁbrosis, pitting and non-pitting edema, square toes, and the
presence of a positive Stemmer sign (the inability to grasp
the skin of the dorsum of the second toe). Lymphedema
was diagnosed clinically according to the criteria of the
International Lymphedema Framework13 and after elimi-
nation of other non-lymphatic causes of edema. No patients
had signs or symptoms of arterial disease nor any other
medical condition that could have affected limb swelling
(i.e., dependency edema due to orthopedic, rheumato-
logical, neurological, or post-radiation problems). Systemic
causes such as renal, hepatic, or cardiac failure have been
excluded clinically or by routine laboratory testing. All pa-
tients underwent duplex scanning of the deep and super-
ﬁcial venous system to assess venous dysfunction and rule
out deep vein thrombosis or post-thrombotic changes. All
patients with advanced chronic venous insufﬁciency with
CEAP classiﬁcation C3 or higher were excluded.
FML was performed in all index legs (lymphedema leg)
and in the clinically unaffected contralateral leg after 10 min
of rest in the supine position at room temperature. The
contrast medium is produced by reconstituting FITC-dextran
(molecular weight 150,000 Da) (Bio Chemica, Germany)
with 0.9% potassium chloride solution (MiniPlasco Connect,
B. Braun Medical, Switzerland) to a 25% solution in a sterile
fashion which is then passed through a bacteria ﬁlter. In-
jection of 0.1 mL of FITC-labeled dextran was carried out
into the intradermal layer of the skin using a tuberculin
syringe and a 25 gauge needle under microscopic control.
The most swollen part of the legdthe malleolus or dorsum
of the footdwas selected for injection together with the
same area of the unaffected contralateral limb. From the
intradermal deposit of FITC dextran, the molecule drains
into the lymphatic capillaries and hence into the deeper
lymphatic collectors, where it is no longer visible. In cases of
lymphatic congestion, the dye spreads through the cuta-
neous lymphatic capillaries and a network of lymphatic
capillaries becomes visible using a ﬂuorescent epi-
illumination microscope. FITC is excited by light of a
wavelength of approximately 495 nm and emits light with a
wavelength of approximately 521 nm. A ﬂuorescent light
microscope (Leica Microsystem AG, Heerbrugg, Switzerland)
was used to visualize the lymphatic capillaries ﬁlled with
dye. Ten minutes after injection, the extension of the
ﬂuorescent contrast medium in the lymph capillaries from
the border of the original dye deposit was measured in four
directions (cranio-caudal and medio-lateral) and the
maximum spread was documented.
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evaluation of adverse events between 30 and 60 min after
injection of FITC dextran, and where necessary blood
chemistry and hematology were obtained.
In this cross sectional study the anonymity of the pa-
tient’s data were retained and informed consent was
received according to the requirements of the institutional
ethical review board. The study performance was in
compliance with the principles laid down in the Declaration
of Helsinki. This manuscript was prepared in compliance
with the STARD Initiative checklist for complete and accu-
rate reporting of studies of diagnostic accuracy.14Statistical analysis
Categorical data are presented as frequency and percent-
ages; continuous data are reported as mean and SD. Data
that were not normally distributed are presented as median
and interquartile range and were analyzed by non-
parametric statistics. Basic statistical parameters such as
sensitivity, speciﬁcity, positive and negative predictive
values, and accuracy for lymphedema detection were
calculated. Positive likelihood ratio (LRþ) was deﬁned as
sensitivity/(1 e speciﬁcity) and negative likelihood ratio
(LR) as speciﬁcity/(1 e sensitivity). Receiver operator
characteristic (ROC) curves were calculated to identify the
potential cut off value that has the highest sensitivity and
speciﬁcity for diagnosing lymphedema. A Fisher exact test
statistic was used to compare binary outcome where
appropriate. A two sided p < .05 was considered statisti-
cally signiﬁcant. Data analyses were performed using Stata
software version 10 (Stata, Inc. College Station, TX, USA).
RESULTS
Between March 2008 and February 2014 seventy patients
with unilateral lymphedema of the lower extremity wereTable 1. Clinical data of 70 patients with unilateral leg lymphedema.
Characteristics Num
Lymp
leg n
Women 46 (6
Age, median (25th, 75th quartile), years 45 (2
Primary lymphedema 50 (7
Congenital 0
Lymphedema praecox 20 (2
Lymphedema tarda 30 (4
Secondary lymphedema 20 (2
Acute leg infection 0
Renal failure 0
Hepatic failure 0
Cardiac failure 0
Hypo- or hyperthyroidism 0
Varicose veins, CEAP class C1e2 10 (1
Varicose veins, CEAP class C3-6 0
Obstruction or insufﬁciency of deep vein system 0
Stemmer’s sign 43 (6
Maximum spread of dye, median
(25th, 75th quartile), mm
20 (1
Note. n.a. ¼ not applicable, CEAP, clinic, etiology, anatomy, pathophysincluded for analysis. Detailed clinical data and patient
characteristics are shown in Table 1. Of those lymphedema
patients, 46 (65.7%) were female. The majority of patients
(71%) were diagnosed with primary lymphedema. Based on
the medical history, twenty patients (29%) had secondary
lymphedema.
The injection sites and the maximal spread of the ﬂuo-
rescent dye are given in Table 2. Deposition of the dye and
measurement of the maximal spread of the ﬂuorescence
dye after 10 min are shown in Figs. 1 and 2. Injection of FML
was performed at the ankle and at the dorsal aspect of the
foot. Fig. 3 represents the distribution of the maximal
spread of the ﬂuorescent dye in the index leg and in the
unaffected contralateral leg.
Table 3 represents the test accuracy at different cut off
levels. The 14 mm spread is the overall threshold value of
FML that is associated with 91.4% sensitivity and 85.7%
speciﬁcity, 6.4 LRþ and 0.1 LR for detecting lymphedema.
The positive and negative predictive values were 86.5% and
90.9%, respectively. The area under the ROC curve was 0.89
(95% CI, 0.83e0.95).
When using the 12 mm cut off level, 92% (n ¼ 46) of
primary lymphedema patients had a positive test, whereas
in secondary lymphedema all 20 (100%) of the patients had
a positive test. There was no signiﬁcant difference in
sensitivity (i.e., positive test) between primary or secondary
lymphedema (Fischer exact test p ¼ .32). When comparing
the sensitivity of primary lymphedema with secondary
lymphedema using the 14 mm cut off level, 88% (n ¼ 44) of
tests were positive for primary lymphedema and 100%
(n ¼ 20) for secondary lymphedema patients (Fisher exact
test p ¼ .17).
Intradermal injection of FITC-labeled dextran in the most
swollen part of the lower extremity was well tolerated.
Severe complications and severe adverse events caused by
FITC-labeled dextran were not observed in any patients. Ofber (%) p
hedema
¼ 70 legs
Unaffected
leg n ¼ 70 legs
5.7) n.a
7, 56) n.a.
1.4) n. a.
n. a.
8.6) n. a.
2.9) n. a.
8.6) n.a.
0
0
0
0
0
4.3) 6 (8.6) 0.4
0
0
1.4) 4 (5.7) <0.001
6, 25) 9 (5, 11) <0.001
iology.
Figure 2. Lymphatic microvessel network arising from the dye
deposit in the medial ankle region magniﬁed under microscope.
Table 2. Injection sites of FITC-labeled dextran in the affected leg.
Number (%)
Thigh 2 (2.9%)
Calf 1 (1.4%)
Ankle 29 (41.4%)
Dorsal aspect of the foot 38 (54.3%)
Fluorescence Microlymphography 477particular importance, no edema, necrosis, or tissue lesion
occurred at the site of injection. No systemic allergic or
anaphylactic reaction was observed, and there were no
clinical signs of systemic inﬂammatory reactions. Overall,
there was one minor side effect (1.4%) with a self limiting
minor rash at the injection site. No deaths were observed
during the study.The center of the network represents the dye deposit. The illu-
minated network around the center represents lymphatic capil-
laries of the superﬁcial lymph system of a 28 year old female with
lymphedema where limb elevation alone rarely reduces swelling.DISCUSSION
This study assessed the accuracy of FML in patients with
unilateral lymphedema. The results suggest that FML is a
useful test for assessing lymphedema, with a high sensitivity
but low speciﬁcity for the actual cut off value of 12 mm. It
is now reported that by using elaborate statistical methods
for test accuracy, a cut off value of 14 mm has a better
speciﬁcity and a higher likelihood ratio for a positive test for
detecting lymphedema than the historical cut off value of
12 mm.
FML can be performed as an ofﬁce based test using a
relatively simple technique, yielding real time valuable
clinical information that can be used for counseling the
patient. FML was performed by an almost atraumatic
technique as described by Bollinger et al.9 It can even be
applied in regions with indurated skin or near venous ul-
cers. The only known complication is a local itching reaction
to the ﬂuorescent macromolecular dye resembling the sting
of a mosquito.15 If lymphatic ﬂow into pre-collectors and
collectors are not impeded, FITC-labeled dextran will be
drained by these pre-collectors and collectors and the su-
perﬁcial lymph capillary networks are only ﬁlled to a minor
extent.15 In lymphedema patients, the dye expands rapidlyFigure 1. Intradermal injection of 0.1 mL of 25% solution of FITC
dextran in the dorsum of the foot and ﬂuorescence illumination of
the dye in a female lymphedema patient with reversible edema
where there is accumulation of tissue ﬂuid that subsides with limb
elevation or over night.into the capillary network system as a result of lymph
drainage obstruction and can be visualized with ﬂuorescent
light. The lymphatic system consists of a superﬁcial (epi-
fascial) system that collects lymph from the skin and sub-
cutaneous tissue and a deeper system that drains subfascial
structures such as muscle, bone, and deep blood vessels.4
Thus the injection has to be done intradermally in order
to be visible at the surface. It has also been shown in pri-
mary lymphedema patients after puberty that mean
lymphatic capillary pressure was signiﬁcantly higher than in
healthy controls due to reduced drainage capacity in the
deep channels.16
The current study shows that when clinical criteria were
used as the gold standard for diagnosing lymphedema, the
area under the ROC curve was 0.89 (95% CI, 0.83e0.95),
which is a good overall discriminative diagnostic test at
separating a lymphedema leg from an unaffected leg. The
positive and negative predictive values and positive and
negative LR for different cut off levels of FML were also
analyzed. Once the test has been performed, the sensitivityFigure 3. Box plot analysis of maximal spread of the ﬂuorescence
dye in the superﬁcial lymphatic vessels separated by lymphedema
leg and unaffected contralateral leg (p < .001).
Table 3. Sensitivity (true positive), speciﬁcity (true negative) positive and negative predictive values and likelihood ratios at different cutoff
levels.
Cut off value (mm) Sensitivity Speciﬁcity PPV NPV LRþ* LR Test accuracy
10 94.3% 51.4% 66.0% 90.0% 1.94 0.11 72.9%
12 94.3% 78.6% 81.5% 93.2% 4.40 0.07 86.4%
14 91.4% 85.7% 86.5% 90.9% 6.4 0.1 88.6%
16 75.7% 88.6% 86.9% 78.5% 6.63 0.27 82.1%
Note. PPV ¼ positive predictive value; NPV ¼ negative predictive value; LRþ ¼ positive likelihood ratio; LR ¼ negative likelihood ratio.
478 H.H. Keo et al.and speciﬁcity do not indicate whether a positive result
truly means the presence of the disease. That information is
given by the predictive values. When using a cut off level of
14 mm spread of FML the LR for a positive test substantially
increases from 4.4 (cut off level of 12 mm) to 6.4 without
substantial loss of the negative LR. Furthermore, the posi-
tive predictive value increases from 81.5% to 86.5%
whereas the negative predictive only decreases from 93.2%
to 90.0%, thus suggesting a more accurate diagnostic test
when using the 14 mm cut off spread.
Patients with chronic venous insufﬁciency CEAP class C3
and higher were excluded. In these patients there is not
only microangiopathy of the blood capillaries, but also the
superﬁcial lymphatic skin capillaries at the medial ankle
region are damaged. The lymphatic network visualized after
FITC dextran injection is interrupted by obliteration or is
completely destroyed. Increased leakage and dermal back-
ﬂow of the dye has been reported, thus suggesting that
indurated edema in chronic venous insufﬁciency arises in
part from lymphatic microangiopathy.15 Thus, the approach
is to look ﬁrst for advanced venous disease, and if indicated
to treat it ﬁrst before addressing the lymphatic component.
Lymphedema is diagnosed clinically and in uncertain
cases, the diagnosis can be conﬁrmed through lympho-
scintigraphic imaging.17 It is performed using the intra- or
subcutaneous administration of a radiolabeled large mole-
cule (typically 99 m-technetium-labeled sulfur colloid or
human serum albumin). The agent is administered subcu-
taneously into the interdigital space of the hands or feet.
The limbs are serially imaged with a scintigraphic camera;
this uses radiation and is time-consuming.18 The indication
for its use varies throughout the world. In some centers it is
advocated for virtually all patients with lymphedema,
whereas in others it is rarely used. The high sensitivity of
lymphoscintigraphy has been challenged by the recent work
of indocyanine green lymphography compared with lym-
phoscintigraphy, MRI, and CT.8
Despite the large sample size, there are some limitations
to this study. The currently accepted “gold standard” for the
diagnosis of lymphedema is based on history and clinical
examination. Thus, misclassiﬁcation cannot be entirely ruled
out and may attenuate the results. As seen in the healthy
leg, there were four positive Stemmer signs, although one
showed a dye spread of 17 mm, thus testing positive. The
other three cases had a negative test. Thus the clinical signs
might be due to a local lipohypertrophy. However, as senior
fellows with at least 10 years of experience in vascular
medicine evaluated these patients and as there is a lack ofdeﬁnite causes of unilateral limb swelling, it is believed that
the rate of misclassiﬁcation of lymphedema is rather low.
The speciﬁcity of the test could have been underestimated
as the unaffected leg, which was used as the control, may
show a latent or subclinical condition where swelling is not
evident despite impaired lymph transport, thus giving rise
to a positive test.
Despite these limitations, the results provide valuable
information about the accuracy of FML. Secondly, this study
provides information in terms of real time study and the
practice based usability of FML in detecting lymphedema. A
widespread use of this repeatable test to conﬁrm the
involvement of the lymphatic system as a factor in the
development of chronic edema of the extremities would
help to enhance the diagnosis of patients with chronic leg
swelling. The role of FML is not a substitute for lympho-
scintigraphy but can be used as an alternative diagnostic
test in lymphedema diagnosis; there are still too many
patients with this vascular dysfunction who are under-
diagnosed and undertreated, which can add to patients’
frustration. FML should be considered a tool to provide
more diagnostic accuracy with the means of an objective
and reproducible technical procedure, particularly in pri-
mary lymphedema where clinical diagnosis can be chal-
lenging and an additional imaging test can be of great
interest. A second important role is to use the test when the
patient has already been evaluated by different physicians
giving controversial interpretations regarding their diag-
nosis. In these cases it is reasonable to have an imaging test
to help support the diagnosis. Moreover, as treatment of
lymphedema is associated with relevant and ongoing heath
care costs (e.g., compression stocking, manual physical
lymphatic drainage), diagnosis must be justiﬁed to the
health care provider.
This test can only visualize the superﬁcial lymphatic
network. The deeper drainage system as seen in indoc-
yanine green lymphography cannot be visualized. Recently,
therapeutic lymphangiogenesis to reverse lymphedema by
targeting VEGF receptor 3 or cell therapy to augment
lymphatic neovascularization in animal models have been
shown to be promising.19,20 FML could be used as a base-
line and outcome measure in these studies.
In conclusion, these results support the usefulness of
FML in the evaluation of the chronically swollen limb. The
examination has no known contraindications and the
technique is simple and safe. The cut off value of 14 mm is
the threshold dye spread that offers a high sensitivity and
high speciﬁcity and should therefore be applied.
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